Advertisement
A Pinksheets status of current information indicates that Solos Endoscopy,Inc. will make its current information publicly available through the OTCDisclosure and News Service according to the Pink OTC Markets manual:Guidelines for Providing Adequate Current Information. There are currently1,111 companies trading under current information as opposed to 521 companiestrading under limited information. The 1,111 companies trading under currentinformation represented approximately 65.4% of the total dollar volume tradedduring the month of December 2007, according to Pinksheets.com.
Advertisement
"By upgrading our status to current information, we are demonstrating toour shareholders that we are working hard to increase the value of our stockas we move forward with our business strategy over the next several months,"stated Bob Segersten, President of Solos Endoscopy, Inc.
Please click on the link to view the Guidelines for Providing AdequateCurrent Information.(http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf)
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission isto develop and market breakthrough technology, applications, medical devices,and procedural techniques for the screening, diagnosis, treatment andmanagement of medical conditions. Backed by technical support, Solos' salesteam can help make the right buying decisions for the hospital, surgerycenter, or physician office. Additional information is available on theCompany's website at: http://www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within themeaning of Section 27A of the Securities Act of 1933 and Section 27E of theSecurities Act of 1934. Statements contained in this release that are nothistorical facts may be deemed to be forward-looking statements. Investors arecautioned that forward-looking statements are inherently uncertain. Actualperformance and results may differ materially from that projected or suggestedherein due to certain risks and uncertainties including, without limitation,ability to obtain financing and regulatory and shareholder approval foranticipated actions.
SOURCE Solos Endoscopy, Inc.
